LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress

What happened: LB Pharmaceuticals (Nasdaq: LBRX) presented four posters at the 39th ECNP Congress in Munich, including new preclinical data on LB-102's mechanism of action and updates on late-stage programs. Key numbers: Congress held October 10-13, 2026. Posters presented Saturday, October 10, 2026, 12:00-1:25 pm CEST. Poster PS01-1019. Why it matters: The company said the data strengthen the scientific rationale for developing LB-102 in mood disorders and highlight a potential mechanism for addressing symptoms such as anhedonia common across neuropsychiatric disorders. Market: -3.5% by next close ($35.93 on Oct 12), +66.3% YTD

LB Pharmaceuticals (Nasdaq: LBRX) presented four posters at the 39th ECNP Congress in Munich, including new preclinical data on LB-102's mechanism of action and updates on late-stage programs.

The company said the data strengthen the scientific rationale for developing LB-102 in mood disorders and highlight a potential mechanism for addressing symptoms such as anhedonia common across neuropsychiatric disorders. Market: -3.5% by next close ($35.93 on Oct 12), +66.3% YTD